0
0
Read Time:12 Second
NEW DELHI: Despite a robust performance by homegrown pharma companies in the June quarter, driven by improved growth in the US markets, analysts and investors are closely monitoring the sector’s growth prospects. Since 1 April, the Nifty Pharma index…
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %